Results 91 to 100 of about 894,362 (295)

DNA Polymerases and Diseases

open access: yes, 2006
In this chapter, we would like to highlight the possible connections between DNA polymerases, the main enzymes in DNA metabolism, and human diseases, also critically evaluating those cases where the experimental data are not fully convincing. To this aim, we will first give a short overview of the three main DNA metabolic events, namely replication ...
Ramadan, K, Maga, G, Hübscher, U
openaire   +3 more sources

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

open access: yesMolecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci   +6 more
wiley   +1 more source

The Binding of DNA Polymerase to Polyoma DNA

open access: yesJournal of General Virology, 1969
Summary DNA polymerase from unpurified extracts of either infected or serumtreated resting mouse embryo cells was bound to double-stranded polyoma DNA and the complex could be separated from the free enzyme and other protein by zone centrifugation through sucrose gradients.
J. D. Pitts, M. Fried
openaire   +3 more sources

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren   +16 more
wiley   +1 more source

IS DNA POLYMERASE A CYTOPLASMIC ENZYME? [PDF]

open access: bronze, 1962
David M. Prescott   +2 more
openalex   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

open access: yesMolecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo   +18 more
wiley   +1 more source

Two Species of DNA Polymerase Isolated from Escherichia coli [PDF]

open access: bronze, 1967
Axel Lezius   +3 more
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy